Literature DB >> 8761371

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland.

A Auvinen1, T Tammela, U H Stenman, I Uusi-Erkkilä, J Leinonen, F H Schröder, M Hakama.   

Abstract

The possibility of screening the general population for prostate cancer using serum prostate-specific antigen (PSA) level (alone or in combination with other tests) as screening test has recently been discussed. A number of studies are on the way, but the published reports have almost exclusively been based on men volunteering for screening. We assessed the feasibility of a screening study based on men identified from a central population registry. A random sample of 600 men in the age groups 55, 60 and 65 years was identified from the Finnish Population Registry as the study population. Half of them were randomised to the intervention group and an invitation to participate was sent to them. The participation rate was 77% (230 out of 300). Twenty-five men had a serum PSA concentration of 4.0 micrograms l-1 or above and were invited for further examination including digital rectal examination, transrectal ultrasound and transrectal Tru-cut biopsies (directed and/or random). Six cases of cancer were detected among the 230 participating men, which corresponds to a detection rate of 2.6% and a positive predictive value of 24%. The number of cases detected is equivalent to the expected number of prostate cancer cases during a 10 year follow-up in this population. The ratio of free to total PSA was also measured and a cut-off level of 0.20 was chosen. Its use as an additional criterion of the screening test would have decreased the prevalence of false-positive screening tests from 8% (19 of 230) to 3% (7 of 230) at a cost of missing one of the six cancers compared with serum total PSA concentration alone. Of the six cancers, five were clinically regarded as localised and locally confined disease was confirmed pathologically in four of them. In conclusion, a population-based study in Finland seems feasible and the properties of the PSA test can be regarded as suitable for a randomised screening study. Thus, all prerequisites for a multicentre study, which is planned, seem to exist.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761371      PMCID: PMC2074672          DOI: 10.1038/bjc.1996.402

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.

Authors:  C Mettlin; G P Murphy; F Lee; P J Littrup; A Chesley; R Babaian; R Badalament; R A Kane; F K Mostofi
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

2.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.

Authors:  W J Catalona; D S Smith; T L Ratliff; J W Basler
Journal:  JAMA       Date:  1993-08-25       Impact factor: 56.272

3.  Complex formation between PSA isoenzymes and protease inhibitors.

Authors:  J Leinonen; W M Zhang; U H Stenman
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

4.  Prostate-specific antigen as predictor of prostate cancer in black men and white men.

Authors:  A S Whittemore; C Lele; G D Friedman; T Stamey; J H Vogelman; N Orentreich
Journal:  J Natl Cancer Inst       Date:  1995-03-01       Impact factor: 13.506

5.  Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.

Authors:  G K Zagars; A Pollack; V S Kavadi; A C von Eschenbach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-05-15       Impact factor: 7.038

6.  Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years.

Authors:  P C Walsh; A W Partin; J I Epstein
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

7.  Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

Authors:  W J Catalona; J P Richie; J B deKernion; F R Ahmann; T L Ratliff; B L Dalkin; L R Kavoussi; M T MacFarlane; P C Southwick
Journal:  J Urol       Date:  1994-12       Impact factor: 7.450

8.  Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project.

Authors:  C Mettlin; P J Littrup; R A Kane; G P Murphy; F Lee; A Chesley; R Badalament; F K Mostofi
Journal:  Cancer       Date:  1994-09-01       Impact factor: 6.860

9.  Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.

Authors:  U H Stenman; M Hakama; P Knekt; A Aromaa; L Teppo; J Leinonen
Journal:  Lancet       Date:  1994-12-10       Impact factor: 79.321

10.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

Authors:  P H Gann; C H Hennekens; M J Stampfer
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272

View more
  3 in total

1.  Mass screening of prostate cancer in Changchun City of China.

Authors:  Xiaomeng Li; Itiro Tsuji; Masaaki Kuwahara; Haifeng Zhang; Hongliang Wang; Ling Zhang; Guoyi Ji; Xuejian Zhao
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

2.  Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels.

Authors:  R M Hoffman; D L Clanon; B Littenberg; J J Frank; J C Peirce
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

Review 3.  Symptomatic diagnosis of prostate cancer in primary care: a structured review.

Authors:  William Hamilton; Deborah Sharp
Journal:  Br J Gen Pract       Date:  2004-08       Impact factor: 5.386

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.